Minnesota will be among the first states in the country to host federally supported sites where COVID-19 patients can access both tests and treatment.
The White House announced Thursday that it will send clinical personnel to Minnesota to staff existing state-run testing locations, transforming them into “test-to-treat” sites where eligible patients can get a prescription for the antiviral drug Paxlovid. Rhode Island, New York, Illinois and Massachusetts will get similar federal resources.
In Minnesota, teams of doctors, nurse practitioners and physicians' assistants will be able to write prescriptions for patients who test positive for COVID at test-to-treat sites, said Erin McLachlan, health care preparedness program manager with the Minnesota Department of Health (MDH). The clinicians are expected to arrive in mid-June, she said.
“We’ve always had a good partnership with the feds, and when we heard that this would be an asset that would be eligible to us, we applied for it,” McLachlan said. “We’re looking forward to having them come.”
The Food and Drug Administration (FDA) in December 2021 gave emergency use authorization for Paxlovid, a Pfizer drug that has been shown to reduce the risk of hospitalization and death from COVID. It’s now available at more than 2,500 test-to-treat locations nationwide, according to the White House, and prescriptions have jumped from about 27,000 a week to more than 182,000.
Not everyone who tests positive for COVID will be able to get a Paxlovid prescription, however. Eligibility is determined based on risk of severe illness, McLachlan said.
“If you’re younger and you’re vaccinated, you probably won’t get that sick with COVID,” she said. “We’re trying to keep the oral antivirals for those that would need them the most, or would get most sick from COVID.”
Paxlovid has some interactions with other drugs, so eligible patients may instead be referred to a local health care system to get the monoclonal antibody treatment bebtelovimab, McLachlan said.